Brown Advisory Inc. lifted its position in Bruker Co. (NASDAQ:BRKR – Get Rating) by 1.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,122,273 shares of the medical research company’s stock after acquiring an additional 11,295 shares during the period. Brown Advisory Inc.’s holdings in Bruker were worth $72,284,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Massachusetts Financial Services Co. MA raised its holdings in Bruker by 69.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 2,754,108 shares of the medical research company’s stock worth $231,097,000 after buying an additional 1,131,375 shares during the period. State Street Corp raised its holdings in Bruker by 41.1% during the 4th quarter. State Street Corp now owns 2,933,413 shares of the medical research company’s stock worth $246,143,000 after buying an additional 854,907 shares during the period. TD Asset Management Inc. raised its holdings in Bruker by 41.6% during the 4th quarter. TD Asset Management Inc. now owns 1,893,900 shares of the medical research company’s stock worth $158,917,000 after buying an additional 556,210 shares during the period. Goldman Sachs Group Inc. raised its holdings in Bruker by 56.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,291,366 shares of the medical research company’s stock worth $108,359,000 after buying an additional 467,064 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in shares of Bruker by 3,212.3% in the fourth quarter. Principal Financial Group Inc. now owns 349,552 shares of the medical research company’s stock valued at $29,331,000 after purchasing an additional 338,999 shares during the last quarter. 76.09% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
BRKR has been the topic of a number of recent research reports. StockNews.com downgraded shares of Bruker from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 16th. The Goldman Sachs Group lowered their price objective on shares of Bruker from $73.00 to $60.00 and set a “sell” rating on the stock in a report on Wednesday, April 13th.
Bruker Price Performance
Bruker (NASDAQ:BRKR – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The medical research company reported $0.45 EPS for the quarter, hitting analysts’ consensus estimates of $0.45. Bruker had a net margin of 11.06% and a return on equity of 31.36%. During the same quarter in the previous year, the business earned $0.44 earnings per share. On average, research analysts expect that Bruker Co. will post 2.3 EPS for the current fiscal year.
Bruker Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 17th. Shareholders of record on Wednesday, June 1st were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Tuesday, May 31st. This represents a $0.20 dividend on an annualized basis and a yield of 0.32%. Bruker’s dividend payout ratio (DPR) is 11.05%.
Bruker Company Profile
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies.
- Get a free copy of the StockNews.com research report on Bruker (BRKR)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.